The Fetal Medicine Foundation (FMF) Germany after 20 Years – Quality Assurance of Ultrasound Examinations during First Trimester Screening

E. Merz; Ch. Thode; B. J. Hackelöer; B. Eiben; R. Faber; S. Tercanli; E. Huda; S. Wellek

doi:10.1055/a-1745-6879

Ultraschall in der Medizin - European Journal of Ultrasound, Table of Contents

Ultraschall Med 2022; 43(02): 115-119
DOI: 10.1055/a-1745-6879

Editorial

The Fetal Medicine Foundation (FMF) Germany after 20 Years – Quality Assurance of Ultrasound Examinations during First Trimester Screening

20 Jahre Fetal Medicine Foundation (FMF) Deutschland – Ein Beitrag zur Qualitätssicherung der Ultraschalluntersuchung beim Ersttrimester-Screening

E. Merz

¹Centre for ultrasound and prenatal medicine, Frankfurt/Main, Germany

,

Ch. Thode

²amedes MVZ für Laboratoriumsmedizin, Göttingen, Germany

,

B. J. Hackelöer

³Amedes experts Barkhof, Germany

,

B. Eiben

⁴Institut für Laboratoriumsmedizin und Klinische Genetik, Essen, Germany

,

R. Faber

⁵Centre for prenatal medicine, Leipzig, Germany

,

S. Tercanli

⁶Ultraschall Freie Strasse Basel, Switzerland

,

E. Huda

⁷FMF Audit Centre Germany, Adelebsen, Germany

,

S. Wellek

⁸Department of Medical Biostatistics, Epidemiology and Informatics of the University of Mainz, Mainz, Germany

⁹Department of Biostatistics, CIMH Mannheim, Mannheim Medical School of the University of Heidelberg, Mannheim, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Snijders RJ, Noble P, Sebire N. et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346
2 Nicolaides KH, Cicer S, Liao AW. One stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation. Prenat Neonat Med 2000; 5: 145-154
3 Spencer K, Souter V, Tul N. et al. A rapid screening program for trisomy 21 at 10-14 weeks using fetal nuchal tranclucency, maternal serum free ß-hCG and PAPP-A. Ultrasound Obstet Gynecol 1999; 13: 231-237
4 Cicero S, Avgidou K, Rembouskos G. et al. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195 (01) 109-114
5 Faiola S, Tsoi E, Huggon IC. et al. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scan. Ultrasound Obstet Gynecol 2005; 26 (01) 22-27
6 Kagan KO, Valencia C, Livanos P. et al. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33 (01) 18-22
7 Borrell A, Gonce A, Martinez JM. et al. First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn 2005; 25 (10) 901-905
8 Merz E, Thode C, Alkier A. et al. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med 2008; 29 (06) 639-645
9 Merz E, Thode C, Eiben B. et al. Individualized correction for maternal weight in calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med 2011; 32 (01) 33-39
10 Merz E, Thode C, Eiben B. et al. Prenatal Risk Calculation (PRC) 3.0: An extended DoE-based first-trimester screening algorithm allowing for early blood sampling. Ultrasound Int Open 2016; 2 (01) E19-E26
11 Lo YM, Chan KC, Sun H. et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010; 2 (61) 61ra91
12 Eiben B, Krapp M, Borth H. et al. Single nucleotide polymorphism-based analysis of cell-free fetal DNA in 3000 cases from Germany and Austria. Ultrasound Int Open 2015; 1 (01) E8-E11
13 Syngelaki A, Chelemen T, Dagklis T. et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011; 31 (01) 90-102
14 Kagan KO, Hoopmann M, Hammer R. et al. Screening for chromosomal abnormalities by first trimester combined screening and noninvasive prenatal testing. Ultraschall Med 2015; 36 (01) 40-46
15 Schmid M, Klaritsch P, Arzt W. et al. Cell-free DNA testing for fetal chromosomal anomalies in clinical practice: Austrian-German-Swiss recommendations for non-invasive prenatal tests (NIPT). Ultraschall Med 2015; 36 (05) 507-510
16 Kozlowski P, Burkhardt T, Gembruch U. et al. DEGUM, ÖGUM, SGUM and FMF Germany recommendations for the implementation of first-trimester screening, detailed ultrasound, cell-free DNA screening and diagnostic procedures. Ultraschall Med 2019; 40 (02) 176-193